KDR and clear cell renal carcinoma: For metastatic clear cell renal cell carcinoma, vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as sunitinib, pazopanib and cabozantinib, were recommended as the first-line systemic therapy in the past 15 years [1–3].